Visualization of Anti-angiogenic Effects With Perfusion Computed Tomography (CTP) (AVA-CTP)

Inclusion Criteria:

• Age ≥ 18 years, male or female
• Signed written informed consent
• Patients with histologically confirmed diagnosis of colorectal cancer with hepatic metastases who are candidates for systemic treatment.

• Confirmation of metastatic liver disease within one month prior to inclusion in one of the following radiological procedures:

  • Contrast-enhanced spiral computed tomography showing at least one liver nodule ≥ 20 mm in longest diameter according to RECIST 1.1 criteria
  • MR imaging of the liver with liver lesions suspicious for metastases
  • PET computed tomography (PET/CT) with liver lesions suspicious for metastases
• Patient is eligible and designated for treatment with standard-of-care first-line bevacizumab-containing, fluoropyrimidine-based chemotherapy.
• ECOG performance status ≤ 2 (see appendix)

Exclusion Criteria:

• Inability or unwillingness to comply with the participation requirements
• History of untreated hyperthyreosis
• History of intolerance of or allergy to iodine contrast media according to CTCAE V4.03
• Calculated creatinine clearance < 45 ml/min
• For fertile women: positive urine pregnancy test or lactation.
• Known or suspected non-compliance, drug or alcohol abuse
• Life expectancy of less than 3 months
• Participation in another interventional trial with an investigational medicinal product (IMP) and within 30 days prior to screening